# Dimitrios Skaltsas

> Dimitrios Skaltsas is the co-founder and CEO of Intelligencia AI, a New York enterprise software company that uses machine learning and curated biomedical data to estimate the probability that a drug candidate will win regulatory approval. Trained as a lawyer in Athens and London, he spent more than a decade at McKinsey, where he built and led New Ventures' big-data and AI work for pharmaceutical R&D before co-founding Intelligencia with Vangelis Vergetis in 2017. Under his leadership the company raised a Series A, was named one of Forbes's Top AI Companies to Watch, secured a U.S. patent for its probability-of-success assessments, and landed on the Inc. 5000. He is also an Executive in Residence at INSEAD.

- **Role:** Co-Founder & CEO at Intelligencia AI
- **Organizations:** Intelligencia AI, INSEAD, McKinsey & Company
- **From:** Greece
- **Nationality:** Greek
- **Education:** Law degree (LLB), University of Athens, Law, University College London (UCL), MBA (Class of 2011J), INSEAD
- **Known for:** Co-founded and leads Intelligencia AI, an enterprise AI platform used to assess drug-approval probability and de-risk clinical development, Built and led McKinsey New Ventures' big-data and AI practice for pharmaceutical R&D, Raised approximately $15.5 million in total funding, including a Series A

## Career timeline

- **pre-2011** — Trained and practiced as a lawyer after law studies at the University of Athens and UCL; briefly returned to school for engineering studies
- **2011** — Earned MBA from INSEAD (Class of 2011J)
- **2010s** — Management consultant at McKinsey & Company, advising healthcare and life sciences clients across North America, Europe and the Middle East
- **2016** — Became Domain Lead in Big Data and AI for Pharmaceutical R&D at McKinsey New Ventures, pioneering ML-enabled enterprise products in life sciences
- **2017** — Co-founded Intelligencia AI in New York with Vangelis Vergetis
- **2021** — Closed Series A funding; Intelligencia named one of Forbes's Top AI Companies to Watch
- **2024** — Intelligencia awarded U.S. patent for probability-of-success assessments; named to Inc. 5000 and Inc. Regional (Northeast) lists

## Achievements

- Co-founded and leads Intelligencia AI, an enterprise AI platform used to assess drug-approval probability and de-risk clinical development
- Built and led McKinsey New Ventures' big-data and AI practice for pharmaceutical R&D
- Raised approximately $15.5 million in total funding, including a Series A
- Company named one of Forbes's Top AI Companies to Watch (2021)
- Secured a U.S. patent for Intelligencia's probability-of-success methodology (2024)
- Named to the Inc. 5000 and Inc. Regional Northeast lists (2024)
- Executive in Residence at INSEAD, contributing to digital transformation and innovation executive-education programs

## Latest updates

- **2024** — Intelligencia AI received a U.S. patent for its probability-of-success assessments and debuted on the Inc. 5000 and Inc. Regional Northeast lists.

## Links

- Website: https://intelligencia.ai
- LinkedIn: http://www.linkedin.com/in/dimitriosskaltsas

---

Profile page: https://yespress.io/dimitrios-skaltsas
Published by YesPress — https://yespress.io
Last updated: 2026-07-17